Biosafety

NBA, NFL, NHL and MLS Teams Choose Biosafety Startup, R-Zero, as their UV-C Disinfection Solution

Retrieved on: 
Monday, March 8, 2021
Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210308005112/en/
    R-Zero's Arc at Golden 1 Center in downtown Sacramento, California.
  • With Arc, which retails at a fraction of the price of traditional UV-C solutions, R-Zero is effectively disrupting a legacy industry.
  • Unlike chemical disinfection, on which sports facilities have traditionally relied, Arc is eco-friendly, highly effective, and addresses airborne pathogens.
  • R-Zero is the first biosafety company dedicated to making the spaces we all live, learn, work, and play safer and clinically clean.

TOMI Environmental Completes Study With University of Virginia Demonstrating Its Disinfection Unit Achieves Kill on SARS CoV-2 Virus in 5 Seconds

Retrieved on: 
Wednesday, January 27, 2021

There was reduction in the number of SARS CoV-2 PFUs in all exposure methods used to the point where there was no detectable viable coronavirus.

Key Points: 
  • There was reduction in the number of SARS CoV-2 PFUs in all exposure methods used to the point where there was no detectable viable coronavirus.
  • The successful study was conducted at the University of Virginias Biosafety Level 3 facility, which is approved for Select Agent research by the Centers for Disease Control and Prevention.
  • Represented by the SteraMist brand of products, iHP produces a germ-killing aerosol that works like a visual non-caustic gas.
  • We undertake no obligation to update these forward-looking statements after the date of this release.

R-Zero Poised to be a Breakthrough Leader in Enterprise Biosafety with Record Sales in First Year

Retrieved on: 
Thursday, January 14, 2021
Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210114005863/en/
    R-Zero's Hospital-Grade UV-C Device, Arc, Destroys 99.99% of Surface and Airborne Pathogens.
  • The fact we did so with a hardware product makes this an even bigger accomplishment.
  • We believe were on a top-decile growth path, and looking at our future product roadmap, were confident R-Zeros best days are still ahead.
  • R-Zero is the first biosafety company dedicated to making the spaces we all live, learn, work, and play safer and clinically clean.

Air Canada Receives APEX’s Diamond Status Certification For Its CleanCare+ Biosafety Program in Response to COVID-19

Retrieved on: 
Tuesday, January 12, 2021

The Diamond certification means that Air Canada has been recognized for reaching hospital grade levels of biosecurity, measures that have been implemented since very early on during the pandemic.

Key Points: 
  • The Diamond certification means that Air Canada has been recognized for reaching hospital grade levels of biosecurity, measures that have been implemented since very early on during the pandemic.
  • Air Canada has been a leader in introducing new science-based measures in response to COVID-19, such as introducing at the very beginning of the pandemic, its comprehensive biosafety program, Air Canada CleanCare+.
  • In 2020, Air Canada was named Global Traveler's Best Airline in North America received for second straight year.
  • For more information, please visit: aircanada.com/media , follow Air Canada on Twitter and LinkedIn , and join Air Canada on Facebook .

R-Zero Emerges as Leading Primary Education Choice for UV-C disinfection

Retrieved on: 
Wednesday, December 9, 2020

SAN FRANCISCO, Dec. 9, 2020 /PRNewswire-PRWeb/ --R-Zero, a pioneering biosafety company dedicated to reducing spread of infectious disease, has become a leading UV-C disinfection solution for our nation's education system.

Key Points: 
  • SAN FRANCISCO, Dec. 9, 2020 /PRNewswire-PRWeb/ --R-Zero, a pioneering biosafety company dedicated to reducing spread of infectious disease, has become a leading UV-C disinfection solution for our nation's education system.
  • Manual disinfection, on which schools have historically relied, is time- and labor-intensive, error-prone, and does not address airborne pathogens.
  • R-Zero and its partners in education envision a future for UV-C disinfection technology beyond the COVID-19 pandemic.
  • In our new normal, R-Zero and its partners across the education sector see disinfection technologies, like UV-C, becoming part of standard infection prevention protocols.

Biosafety Company, R-Zero, Joins Government Advisory Organization, International Ultraviolet Association

Retrieved on: 
Wednesday, December 9, 2020

R-Zero, a biosafety company dedicated to developing hospital-grade UV-C disinfection technologies to reduce the spread of infectious disease, today announced its official membership with the International Ultraviolet Association, Inc. (IUVA), the leading UV educational and advocacy organization.

Key Points: 
  • R-Zero, a biosafety company dedicated to developing hospital-grade UV-C disinfection technologies to reduce the spread of infectious disease, today announced its official membership with the International Ultraviolet Association, Inc. (IUVA), the leading UV educational and advocacy organization.
  • We believe UV-C is a critical tool to fight not only the novel coronavirus today, but all pathogens that threaten human health.
  • As part of R-Zeros affiliation with IUVA, CEO and co-founder, Grant Morgan, has also joined the organizations Coronavirus Response Task Force.
  • About R-Zero: R-Zero is the first biosafety company dedicated to making all common spaces safer and clinically clean.

$12.9 Million Biosafety Cabinets Market - Global COVID-19 Impact Analysis & Forecasts 2020-2027 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 17, 2020

The "Biosafety Cabinets Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Type; End User; and Geography" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Biosafety Cabinets Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Type; End User; and Geography" report has been added to ResearchAndMarkets.com's offering.
  • The global biosafety cabinets market is expected to reach US$ 312.90 million by 2027 from US$ 166.67 million in 2019.
  • The report highlights trends prevailing in the global biosafety cabinets market and the factors driving market along with those that act as hindrances.
  • The biosafety cabinets market is expected to grow owing to factors such as increasing prevalence of infectious diseases and technology advancements in biosafety cabinets.

British High Commissioner Dr. Christian Turner Inaugurates Robot-Operated Covid-19 Testing Lab in Islamabad

Retrieved on: 
Sunday, November 15, 2020

Built in the United Kingdom by Opencell UK, the laboratory is a Biosafety Level 2 plus (BSL-2+) facility built to ISO 15189 standards.

Key Points: 
  • Built in the United Kingdom by Opencell UK, the laboratory is a Biosafety Level 2 plus (BSL-2+) facility built to ISO 15189 standards.
  • The state-of-art lab is specified to meet the requirements for high throughput Covid-19 RT-qPCR testing.
  • Due to the use of 5 liquid handling robots, this lab requires as little as 6 staff members to operate all the shifts.
  • While speaking at the event, High Commissioner Dr. Christian Turner thanked Ambassador Ali Jehangir Siddiqui for "making him excited about the project.

R-Zero Raises $15M, Democratizing Access to Biosafety Technologies in the COVID-19 Era and Beyond

Retrieved on: 
Tuesday, November 10, 2020

As part of the round, Ira Ehrenpreis, Managing Partner at DBL Partners, has joined R-Zeros Board of Directors.

Key Points: 
  • As part of the round, Ira Ehrenpreis, Managing Partner at DBL Partners, has joined R-Zeros Board of Directors.
  • Through innovation and cost reduction, R-Zero democratizes access to safety for businesses and communities alike.
  • The need for innovation around how we create safer spaces has never been more urgent and apparent.
  • R-Zero is the first biosafety company dedicated to making the spaces we all live, learn, work, and play safer and clinically clean.

New laboratory development can speed up validation of effectiveness for potential COVID-19 treatments

Retrieved on: 
Thursday, October 15, 2020

This enables testing of new COVID-19 drug therapies against the replicon outside of the more expensive biosafety level-2 laboratories.

Key Points: 
  • This enables testing of new COVID-19 drug therapies against the replicon outside of the more expensive biosafety level-2 laboratories.
  • Any pharmaceutical company would be able to use the lab-created replicons to rapidly screen a library of potential drug treatments for effectiveness against COVID-19.
  • "Our development, called the "Flexicon", can make treatment testing much faster and more accessible to many labs around the world."
  • Fanshawe College is one of Ontario's largest colleges, helping people unlock their potential and achieve success for more than 50 years.